Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

ing a MACE rate of 3.6 percent (one patient) at two years. MACE is a composite clinical measure of safety and efficacy outcomes, defined as any event that resulted in re-treatment of the treated artery lesion (ischemia-driven target lesion revascularization), heart attack (myocardial infarction) or cardiac death.

"Based on the strong clinical outcomes from the first stage of Abbott's bioabsorbable device trial, interventional cardiologists have been eager to enroll their patients into the second stage of the trial," said John Ormiston, M.D., medical director at Mercy Hospital in Auckland, New Zealand, and co-principal investigator in the ABSORB trial. "If the bioabsorbable stent continues to perform well in this trial and subsequent larger trials with more complex narrowings, bioabsorbable device technology may become the new standard of care for patients with coronary artery disease."

Abbott is the only company with long-term clinical data (out to two years) evaluating the safety and performance of a fully bioabsorbable drug eluting coronary stent. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as absorbable sutures. As with a metallic stent, Abbott's bioabsorbable device is designed to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable device is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott has been on the front lines of innovation in stent technology, and the fully bioabsorbable device is on track to become a clinical reality for patients," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Abbott is the furthest ahead in its clinical programs to bring a bioabsorbable drug eluting device to patients, and the company is com
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Research and Markets  has announced the addition of ... Global Forecast to 2019" report to their offering. ... equipment market is categorized on the basis of product ... expected to register the highest growth rate in the ... 2019). This high growth is attributed to the rising ...
(Date:10/25/2014)... 2014 Research and Markets ... the "Global and Chinese Hemodialysis Concentrates Industry ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , Global ... a professional and in-depth study on the current ... focus on the Chinese situation. The ...
(Date:10/25/2014)... , Oct. 24, 2014 In conjunction ... quarter 2014 financial results press release, you are invited ... broadcast live over the internet on Monday, November 3, ... Time). A live audio webcast of the ... http://www.durect.com and clicking "Investor Relations."  If you ...
Breaking Medicine Technology:Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 2Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 3Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2
... Ind., Feb. 24, 2011 Symmetry Medical Inc. (NYSE: ... orthopaedic device industry and other medical markets, announced fourth quarter and ... 2011.Fourth QuarterTotal Year (In millions, except per share data) , ... 96.0 , $ 76.4 , 26%$ 360.8 , $ 365.9 , ...
... Mass. and SYDNEY, Feb. 24, 2011 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced revenues of $20.9 million for the fourth ... million in revenues for the fourth quarter of 2009, ...
Cached Medicine Technology:Symmetry Medical Reports Fourth Quarter and Full Year 2010 Financial Results 2Symmetry Medical Reports Fourth Quarter and Full Year 2010 Financial Results 3Symmetry Medical Reports Fourth Quarter and Full Year 2010 Financial Results 4Symmetry Medical Reports Fourth Quarter and Full Year 2010 Financial Results 5Symmetry Medical Reports Fourth Quarter and Full Year 2010 Financial Results 6Symmetry Medical Reports Fourth Quarter and Full Year 2010 Financial Results 7Symmetry Medical Reports Fourth Quarter and Full Year 2010 Financial Results 8Symmetry Medical Reports Fourth Quarter and Full Year 2010 Financial Results 9HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 2HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 3HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 4HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 5HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 6
(Date:10/25/2014)... Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Diagnostics listing their product specification, capacity, Production ...
(Date:10/25/2014)... October 25, 2014 Mesothelioma researchers are ... to receive pemetrexed (Alimta), after his combination drug therapy ... full story , just posted on the Surviving Mesothelioma ... Tokushukai Medical Center in Japan suggests that “maintenance therapy” ... patients who cannot tolerate higher doses of cisplatin. ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Not getting the right ... colitis, a new study suggests. Those who sleep ... hours per night may be more prone to developing ... researchers report. The study authors concluded that duration and ... among patients with inflammatory bowel diseases. "Both short ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 ... spot increased risks for certain cancers, one might think that ... But a new study suggests that, at least with colon ... their genes doubled their risk of colon cancer were no ... "It didn,t make any difference, not at all," said ...
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... fibers, researchers say, , THURSDAY, Aug. 20 (HealthDay News) ... condition that can impair fertility, requires no surgery and ... experts said the accuracy of the new approach, which ... be replicated, which the researchers also acknowledged. , Until ...
... ... in full swing. Texas and Southwestern Cattle Raisers Association (TSCRA) Insurance Services is helping its ... equipping them with important preventative care measures that will not only save them money, but ... ...
... ... 3rd Annual Clinical Trial Disclosure Workshop (October 6-8, 2009; National Harbor, MD). , ... Horsham, PA, USA (Vocus) August 20, ... Clinical Trial Disclosure Workshop (October 6-8, 2009; National Harbor, MD). , , , , ...
... List of cities and times below. Team will travel in a Motor ... filming comedy commercials against "Obama,s Death Care," including costumes, props and images. ... Aug. 20 The following was released today by Randall Terry, Director, Operation ... see the rage expressed at ,town hall meetings., However, much of this ...
... , , WHITE PLAINS, N.Y. ... August is National Immunization Awareness Month, and while ... The "Sounds of Pertussis", a campaign from the March of Dimes ... educating adults about pertussis prevention, so that they can keep themselves ...
... , WASHINGTON, Aug. 20 The American Red Cross ... the beach along the U.S. East Coast this weekend as experts ... the shore. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) ... Three storm with winds blowing up to 125 mph, and experts ...
Cached Medicine News:Health News:New Way Found to Diagnose Endometriosis 2Health News:New Way Found to Diagnose Endometriosis 3Health News:TSCRA Insurance Services Shares Importance of Back-to-School Preventative Health Care 2Health News:TSCRA Insurance Services Shares Importance of Back-to-School Preventative Health Care 3Health News:DIA 3rd Annual Clinical Trial Disclosure Workshop Offers Strategies for Creating Effective Registries and Results Databanks 2Health News:Healthcare and Abortion: Randall Terry Leads Protests and Press Conferences in 10 Cities in Five States 2Health News:Video: 'Sounds of Pertussis' Campaign Urges Adults to Take Action During National Immunization Awareness Month 2Health News:Video: 'Sounds of Pertussis' Campaign Urges Adults to Take Action During National Immunization Awareness Month 3Health News:Video: 'Sounds of Pertussis' Campaign Urges Adults to Take Action During National Immunization Awareness Month 4Health News:Video: 'Sounds of Pertussis' Campaign Urges Adults to Take Action During National Immunization Awareness Month 5Health News:Video: 'Sounds of Pertussis' Campaign Urges Adults to Take Action During National Immunization Awareness Month 6Health News:American Red Cross Provides Safety Tips for Rip Tides Caused by Hurricane Bill 2
... a comprehensive, authoritative drug reference to ... overdose management, Canadian drug names, OTC ... drug references and tools is included ... (ED, PRIMARY CARE PLUS, CRC, RN, ...
The mission of AHFS DI Essentials (American Hospital Formulary Service) is to provide an evidence-based foundation for safe and effective drug therapy....
... the latest in scientific clinical trial activity ... knowledge resources from CenterWatch. This highly valuable ... monitor and stay abreast of medical breakthroughs ... Clinical Trials, Clinical Trial Results, Newly Approved ...
Allows health professionals to answer consumers' questions regarding safety issues concerning possible drug-herb and drug-food interactions....
Medicine Products: